TC
ESPR

TFS Capital’s Esperion Therapeutics ESPR Stock Holding History

TFS Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-26,510
Closed -$262K – 809
2016
Q2 		$262K Buy
26,510
+15,402
+139% +$255K 0.05% 647
2016
Q1 		$188K Sell
11,108
-11,017
-50% -$177K 0.03% 784
2015
Q4 		$493K Buy
+22,125
New +$558K 0.05% 415
2014
Q1 		– Sell
-23,654
Closed -$325K – 1407
2013
Q4 		$325K Sell
23,654
-12,675
-35% -$184K 0.02% 1050
2013
Q3 		$685K Buy
+36,329
New +$610K 0.03% 727

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return